Financials data is unavailable for this security.
View more
Year on year SMS Pharmaceuticals Ltd had net income fall from a gain of 622.20m to a loss of 70.59m despite flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 60.78% to 72.75%.
| Gross margin | 31.67% |
|---|---|
| Net profit margin | 6.65% |
| Operating margin | 12.11% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2023, cash reserves at SMS Pharmaceuticals Ltd fell by 392.05m. However, the company earned 224.50m from its operations for a Cash Flow Margin of 4.30%. In addition the company used 296.86m on investing activities and also paid 319.69m in financing cash flows.
| Cash flow per share | 8.55 |
|---|---|
| Price/Cash flow per share | 23.45 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -111.35%. Additionally, five year annualized dividend per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.48% |
|---|---|
| Div growth rate (5 year) | 3.71% |
| Payout ratio (TTM) | 7.04% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 975.18 |
More ▼
